Research programme: plasminogen based therapeutics - Omnio/ProMetic Life Sciences

Drug Profile

Research programme: plasminogen based therapeutics - Omnio/ProMetic Life Sciences

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omnio AB
  • Developer Omnio AB; ProMetic Life Sciences
  • Class Anti-inflammatories; Blood products and substitutes; Plasminogen activator enzymes; Proteins
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic foot ulcer; Ear disorders
  • Research Inflammation

Most Recent Events

  • 01 Nov 2017 The Swedish Medical Products Agency approves Clinical Trial Application to initiate a clinical trial of plasminogen therapy in Ear disorders (chronic tympanic membrane perforation)
  • 26 Oct 2017 Preclinical trials in Diabetic foot ulcer in Sweden (SC) before October 2017
  • 26 Oct 2017 The Swedish Medical Products Agency approves Clinical Trial Application to initiate a phase II trial of plasminogen therapy in Diabetic foot ulcer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top